器官移植受者多发性皮肤癌风险:两项行政数据集队列研究
结果显示,Optum和MarketScan中分别有4.5%和13.3%的OTRs至少接受过一次皮肤癌治疗;在首次移植后皮肤癌后2年,后续皮肤癌治疗风险为44.0%至57.0%,发生10次及以上皮肤癌治疗的风险为3.7%至6.6%。
要点
- 移植后发生首次皮肤癌的OTRs中,约半数在2年内发生后续皮肤癌。
- 约1/20的OTRs在首次皮肤癌后2年内发生10次及以上皮肤癌。
- 年龄、皮肤癌史和光化性角化病史是任何皮肤癌的显著风险因素。
核心结论
- 约半数发生至少1次移植后皮肤癌的OTRs在2年内发生后续皮肤癌,约1/20发生10次及以上皮肤癌。
研究设计与样本
- 皮肤癌通过基底细胞癌、鳞状细胞癌和黑色素瘤的诊断加治疗代码识别;OTRs通过4个及以上器官移植诊断代码识别。
主要发现
- 在数据集中首次移植后皮肤癌后2年,OTRs后续皮肤癌治疗风险为44.0%至57.0%,发生10次及以上皮肤癌治疗的风险为3.7%至6.6%。
- 两个数据集中任何皮肤癌的显著风险因素包括年龄、皮肤癌史和光化性角化病史;MarketScan中还包括男性性别和胸部移植。
关键数值与推荐
- 首次移植后皮肤癌后2年:后续皮肤癌治疗风险44.0%至57.0%,10次及以上皮肤癌治疗风险3.7%至6.6%。
临床怎么用
- 识别多发性原发性皮肤癌最高风险的OTRs可能有助于针对性制定预防和早期检测策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: There are limited reports on the risks of multiple primary skin cancers in organ transplant recipients (OTRs). OBJECTIVE: To determine the risks over time and risk factors for OTRs developing (1) any skin cancer posttransplant, (2) a subsequent skin cancer after the first posttransplant skin cancer in the data sets used in the study, and (3) 10 or more skin cancers. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study used data from Optum deidentified electronic health record data set (7.7 million patients) and Truven Health MarketScan insurance claims data set (161 million patients) from 2007 to 2017. Skin cancers were identified using diagnosis plus treatment codes for basal cell carcinoma, squamous cell carcinoma, and melanoma; OTRs were identified using 4 or more diagnosis codes for organ transplant. Data analysis took place from January 1, 2007, to December 31, 2017. MAIN OUTCOMES AND MEASURES: Cumulative risks of (1) any skin cancer treatment posttransplant, (2) a subsequent skin cancer treatment after the first posttransplant skin cancer treatment in our data, and (3) 10 or more skin cancer treatments in OTRs. A Wei-Lin-Weissfeld marginal model was used to evaluate risk factors for any skin cancer. RESULTS: A total of 7390 OTRs in Optum and 133 651 in MarketScan were identified, 4.5% and 13.3% of which had had at least 1 skin cancer treatment, respectively. At 2 years after the initial posttransplant skin cancer in the data sets, OTRs had a 44.0% to 57.0% risk of a subsequent skin cancer treatment and a 3.7% to 6.6% risk of having 10 or more skin cancer treatments. Statistically significant risk factors for any skin cancer included age, history of skin cancer, and history of actinic keratosis in both data sets, and male sex and thoracic transplant in MarketScan. CONCLUSIONS AND RELEVANCE: In this retrospective cohort study, approximately half of the OTRs who developed at least 1 posttransplant skin cancer developed a subsequent skin cancer within 2 years, and approximately 1 in 20 developed 10 or more skin cancers. Identifying OTRs at highest risk for multiple primary skin cancers may help target strategies for prevention and early detection.
引用
- Wehner MR, Niu J, Wheless L, et al. Risks of Multiple Skin Cancers in Organ Transplant Recipients: A Cohort Study in 2 Administrative Data Sets. JAMA Dermatol. 2021. PMID: 34668933. doi:10.1001/jamadermatol.2021.4148
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。